NewCardio Announces Master Services Agreement With Dedicat...(ded and on acceptable terms and general ...),Health

Date:8/5/2009

ded, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

    Investor Contact:
    Hayden IR
    Jeff Stanlis, Partner and VP of Communications
    (602)476-1821
    jeff@haydenir.com

'/>"/>

SOURCE NewCardio, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. NewCardio Leadership to Present Two Abstracts at ISCE Conference
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Announces Positive Results From Third Clinical Validation Study
4. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
5. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
6. Cryo-Cell Announces Celle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
7. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
10. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
11. AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine